News | January 29, 2026
Cupid gets certification for HIV & Hepatitis B test kits, paving way for global expansion
The newly certified kits are designed for early detection and large-scale screening programs
The newly certified kits are designed for early detection and large-scale screening programs
In the SHORE phase 3 study, amlitelimab, used in combination with topical therapies, met all primary and key secondary endpoints at Week 24
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
This marks the second indication for which gumokimab has gained NDA review acceptance
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Improvements were also seen in complete response rates, duration of response, and time to next treatment
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
Subscribe To Our Newsletter & Stay Updated
